亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

會員登錄|免費注冊|忘記密碼|管理入口 返回主站||保存桌面|手機瀏覽|聯系方式|購物車
企業會員第1年

武漢遠城科技發展有限公司集團總部  

精細化工,香精香料,食品添加劑,醫藥原料及中間體等產品

搜索
新聞中心
  • 暫無新聞
產品分類
聯系方式
  • 聯系人:錢鑫
  • 電話:027-50755969
  • 郵件:dhh04@ycphar.com
  • 傳真:027-68886696
  • QQ:2355327120
站內搜索
 
榮譽資質
  • 暫未上傳
友情鏈接
  • 暫無鏈接
首頁 > 供應產品 > 索非那新琥珀酸鹽
索非那新琥珀酸鹽
單價 1.00 / 千克對比
銷量 暫無
發貨 湖北武漢市付款后3天內
庫存 10000千克起訂1千克
品牌 南箭
含量 99%
過期 長期有效
更新 2015-10-06 09:06
 
詳細信息
 索非那新琥珀酸鹽 
中文名稱: 索非那新琥珀酸鹽 
中文同義詞: 1-氮雜雙環[2.2.2]辛烷-8-基-(1S)-1-苯基-3,4-二氫-1H-異喹啉-2-甲酸酯丁二酸鹽;索非那新琥珀酸鹽;琥珀酸素立芬新;琥珀酸索非那新;琥鉑酸索非那新;索非那新琥珀酸;琥珀酸索菲那新;琥珀酸索利那新 
英文名稱: Solifenacin succinate 
英文同義詞: 1-azabicyclo[2.2.2]octan-8-yl (1s)-1-phenyl-3,4-dihydro-1h-isoquinoline-2-carboxylate butanedioic acid;vesicare;solifenacin succinate;IsoprenalinoeSulfate;1-Azabicyclo[2.2.2]octan-8-yl (1S)-1-phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylate butanedioic acid;Butanedioic acid, *pd. with (1S)-(3R)-1-azabicyclo[2.2.2]oct-3-yl 3,4-dihydro-1-phenyl-2(1H)-isoquinolinecarboxylate (1:1);(1R,3R)-1-azabicyclo[2.2.2]octan-3-yl (1S)-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate;(1S)-(3R)-1-Azabicyclo[2.2.2]oct-3-yl 3,4-Dihydro-1-phenyl-2(1H)- isoquinolinecarboxylate Butanedioic Acid 
CAS號: 242478-38-2 
分子式: C23H26N2O2.C4H6O4 
相關類別: API;Solifenacin 
Mol文件: 242478-38-2.mol 
用途: 尿失禁(OAB)泌尿系統用藥
含量:99%
包裝:1g鋁箔袋
©2025 武漢遠城科技發展有限公司集團總部 版權所有   技術支持:化工網   訪問量:4726  
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |